Olivier Michielin
#122,598
Most Influential Person Now
Olivier Michielin's AcademicInfluence.com Rankings
Olivier Michielinchemistry Degrees
Chemistry
#2666
World Rank
#3605
Historical Rank
Organic Chemistry
#402
World Rank
#474
Historical Rank
Olivier Michielinbiology Degrees
Biology
#7516
World Rank
#10453
Historical Rank
Bioinformatics
#83
World Rank
#85
Historical Rank
Download Badge
Chemistry Biology
Why Is Olivier Michielin Influential?
(Suggest an Edit or Addition)Olivier Michielin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules (2017) (5459)
- SwissParam: A fast force field generation tool for small organic molecules (2011) (1282)
- SwissDock, a protein-small molecule docking web service based on EADock DSS (2011) (1255)
- SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules (2019) (1075)
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2017) (980)
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance (2019) (895)
- SwissTargetPrediction: a web server for target prediction of bioactive small molecules (2014) (780)
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients (2015) (480)
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab (2014) (443)
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study (2020) (419)
- iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach (2014) (414)
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma (2011) (386)
- Fast docking using the CHARMM force field with EADock DSS (2011) (356)
- Inhibition of the shade avoidance response by formation of non‐DNA binding bHLH heterodimers (2009) (343)
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity (2015) (339)
- Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. (2007) (336)
- Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma (2016) (327)
- Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response (2014) (319)
- The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor γ Modulator That Promotes Adipogenesis* (2007) (305)
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. (2010) (272)
- Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. (2014) (263)
- Shaping the interaction landscape of bioactive molecules (2013) (259)
- Defining and searching for structural motifs using DeepView/Swiss-PdbViewer (2012) (254)
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer (2018) (251)
- Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. (2016) (221)
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus (2020) (207)
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus (2020) (207)
- Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function (2010) (195)
- SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening (2016) (193)
- EADock: Docking of small molecules into protein active sites with a multiobjective evolutionary optimization (2007) (182)
- Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization (2012) (181)
- Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients (2012) (175)
- Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma (2017) (172)
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2018) (171)
- Pulmonary sarcoid-like granulomatosis induced by ipilimumab. (2012) (170)
- Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma (2002) (170)
- Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. (2003) (169)
- Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. (2009) (162)
- Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. (2015) (162)
- Docking, virtual high throughput screening and in silico fragment-based drug design (2009) (158)
- Rational design of indoleamine 2,3-dioxygenase inhibitors. (2010) (144)
- Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. (2012) (141)
- Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. (2002) (135)
- Structure-Function Characterization and Optimization of a Plant-Derived Antibacterial Peptide (2005) (124)
- Comparison between computational alanine scanning and per‐residue binding free energy decomposition for protein–protein association using MM‐GBSA: Application to the TCR‐p‐MHC complex (2007) (121)
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression (2013) (118)
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. (2019) (118)
- SHP-1 phosphatase activity counteracts increased T cell receptor affinity. (2013) (117)
- Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness* (2012) (114)
- Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. (2016) (112)
- Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. (2013) (104)
- Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex. (2008) (102)
- Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer (2018) (100)
- SwissBioisostere: a database of molecular replacements for ligand design (2012) (98)
- SwissSidechain: a molecular and structural database of non-natural sidechains (2012) (91)
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
- The V‐ATPase proteolipid cylinder promotes the lipid‐mixing stage of SNARE‐dependent fusion of yeast vacuoles (2011) (84)
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). (2018) (83)
- Prevalent Role of TCR α-Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen1 (2003) (82)
- MM–GBSA binding free energy decomposition and T cell receptor engineering (2010) (81)
- Clinical relevance of tumour-associated macrophages (2022) (80)
- Structural and Functional Interaction Sites between Na,K-ATPase and FXYD Proteins* (2004) (77)
- CD3δ Establishes a Functional Link between the T Cell Receptor and CD8* (2003) (76)
- Structure-Function Analyses Point to a Polynucleotide-Accommodating Groove Essential for APOBEC3A Restriction Activities (2010) (76)
- Molecular Basis of Leukocyte Rolling on PSGL-1 (2003) (72)
- Functional dynamics of PDZ binding domains: a normal-mode analysis. (2005) (70)
- Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. (2014) (69)
- First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). (2012) (66)
- Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial (2015) (64)
- MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data (2019) (64)
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial (2014) (63)
- Functional Analysis and Structural Modeling of Human APOBEC3G Reveal the Role of Evolutionarily Conserved Elements in the Inhibition of Human Immunodeficiency Virus Type 1 Infection and Alu Transposition (2009) (59)
- Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma (2021) (59)
- A Combined Computational and Functional Approach Identifies New Residues Involved in pH-dependent Gating of ASIC1a* (2010) (59)
- Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes1 (2001) (59)
- Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. (2014) (58)
- Model Structure of Human APOBEC3G (2007) (58)
- CD8+ Cytotoxic T Lymphocyte Activation by Soluble Major Histocompatibility Complex-Peptide Dimers* (2005) (58)
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. (2021) (57)
- Vaccination‐induced functional competence of circulating human tumor‐specific CD8 T‐cells (2012) (55)
- Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis. (2019) (54)
- TERAVOLT: Thoracic Cancers International COVID-19 Collaboration (2020) (53)
- Binding free energy differences in a TCR-peptide-MHC complex induced by a peptide mutation: a simulation analysis. (2002) (53)
- Blind docking of 260 protein–ligand complexes with EADock 2.0 (2009) (52)
- Gaining momentum: New options and opportunities for the treatment of advanced melanoma. (2015) (51)
- Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors (2003) (50)
- Structure-Based, Rational Design of T Cell Receptors (2013) (50)
- Sequence Determinants of a Microtubule Tip Localization Signal (MtLS)* (2012) (49)
- Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. (2019) (47)
- Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (2021) (47)
- Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma (2016) (47)
- Improving Binding Affinity and Stability of Peptide Ligands by Substituting Glycines with D‐Amino Acids (2013) (47)
- The SIB Swiss Institute of Bioinformatics’ resources: focus on curated databases (2015) (47)
- Structural prediction of peptides bound to MHC class I. (2006) (46)
- Evolving impact of long-term survival results on metastatic melanoma treatment (2020) (46)
- Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors (2017) (46)
- Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope (2016) (45)
- Lymphatic vessel density is associated with CD8+ T cell infiltration and immunosuppressive factors in human melanoma (2018) (44)
- Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public (2017) (44)
- Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027)) (2018) (42)
- Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1157–165 by interacting with its central Met/Trp residues (2008) (42)
- How T cell receptors interact with peptide‐MHCs: A multiple steered molecular dynamics study (2011) (41)
- The peroxisomal enzyme L-PBE is required to prevent the dietary toxicity of medium-chain fatty acids. (2013) (40)
- Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. (2020) (40)
- RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family (2013) (38)
- CD73 expression and clinical significance in human metastatic melanoma (2018) (38)
- The Fourth Transmembrane Segment of the Na,K-ATPase α Subunit (2004) (37)
- In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI (2016) (37)
- A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab (2018) (36)
- CD3 delta establishes a functional link between the T cell receptor and CD8. (2003) (35)
- ECCO essential requirements for quality cancer care: Melanoma. (2018) (34)
- Docking to heme proteins (2009) (34)
- Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma (2017) (34)
- Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. (2021) (33)
- Combined Simulation and Mutagenesis Analyses Reveal the Involvement of Key Residues for Peroxisome Proliferator-activated Receptorα Helix 12 Dynamic Behavior* (2007) (33)
- The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate (2014) (32)
- Use of the FACTS solvation model for protein–ligand docking calculations. Application to EADock (2010) (31)
- Unique Spectrum of Activity of Prosimian TRIM5α against Exogenous and Endogenous Retroviruses (2011) (31)
- Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? (2013) (31)
- Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody. (2013) (31)
- Integrating radiomics into holomics for personalised oncology: from algorithms to bedside (2020) (30)
- Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. (2013) (29)
- Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses (2017) (29)
- Modeling of the TCR-MHC-peptide complex. (2000) (29)
- Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. (2012) (29)
- A practical guide to the handling and administration of talimogene laherparepvec in Europe (2017) (29)
- Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape (2015) (28)
- In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1 (2008) (28)
- 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2). (2016) (28)
- Silencing of both β-TrCP1 and HOS (β-TrCP2) Is Required To Suppress Human Immunodeficiency Virus Type 1 Vpu-Mediated CD4 Down-Modulation (2006) (28)
- Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients (2018) (27)
- Irinotecan-induced interstitial pneumonia. (2004) (27)
- Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes (2011) (27)
- Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies (2016) (27)
- Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy (2021) (27)
- Protein pocket and ligand shape comparison and its application in virtual screening (2013) (27)
- A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) (2015) (27)
- A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide1 (2007) (27)
- Frequent MAGE Mutations in Human Melanoma (2010) (26)
- Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. (2020) (25)
- Expanding molecular modeling and design tools to non‐natural sidechains (2012) (25)
- A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? (2013) (25)
- Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. (2018) (24)
- T cell receptor alpha variable 12‐2 bias in the immunodominant response to Yellow fever virus (2017) (24)
- Identification of human IKK-2 inhibitors of natural origin (Part II): in Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity. (2011) (23)
- Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. (2018) (22)
- Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma (2018) (22)
- The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience (2022) (21)
- Identification of Human IKK-2 Inhibitors of Natural Origin (Part I): Modeling of the IKK-2 Kinase Domain, Virtual Screening and Activity Assays (2011) (21)
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany (2021) (20)
- Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland (2017) (20)
- Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives (2020) (20)
- A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317–326 Peptide* (2014) (20)
- Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. (2007) (20)
- Turning tumors from cold to inflamed to improve immunotherapy response. (2021) (19)
- The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study (2019) (19)
- Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient (2019) (19)
- Homology-based Identification of Capsid Determinants That Protect HIV1 from Human TRIM5α Restriction* (2010) (18)
- TCRep 3D: An Automated In Silico Approach to Study the Structural Properties of TCR Repertoires (2011) (18)
- Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients (2013) (18)
- Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study (2014) (17)
- Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity (2021) (17)
- Structural assessment of single amino acid mutations: application to TP53 function (2006) (17)
- 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis (2021) (17)
- Unmyristoylated MARCKS-related protein (MRP) binds to supported planar phosphatidylcholine membranes. (1998) (16)
- T Cell Recognition of Hapten (1999) (16)
- Herpes simplex encephalitis in adult patients with MASP-2 deficiency (2019) (16)
- 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma (2015) (16)
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
- MYRISTOYLATION-INDUCED COMPACTION OF A MEMBRANE-BINDING PROTEIN (1999) (16)
- 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma (2020) (15)
- The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1). (2017) (15)
- First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver (2020) (15)
- Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss (2019) (15)
- Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. (2021) (14)
- A Template‐Assembled Synthetic Protein Surface Mimetic of the von Willebrand Factor A1 domain Inhibits Botrocetin‐Induced Platelet Aggregation (2004) (14)
- Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. (2020) (14)
- Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. (2014) (14)
- Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding (2020) (13)
- Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support (2014) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Melanoma and other skin tumors (2012) (13)
- Access of Extracellular Cations to their Binding Sites in Na,K-ATPase: Role of the Second Extracellular Loop of the α Subunit (2006) (12)
- Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients (2007) (12)
- A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ). (2017) (12)
- First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). (2010) (11)
- The fourth transmembrane segment of the Na,K-ATPase alpha subunit: a systematic mutagenesis study. (2004) (11)
- Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM) (2012) (11)
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (2022) (11)
- Comment on “MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma” (2018) (11)
- Dendritic cells direct circadian anti-tumour immune responses (2022) (11)
- What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position Paper (2020) (11)
- MedCo: Enabling Privacy-Conscious Exploration of Distributed Clinical and Genomic Data (2017) (10)
- [A practical guide for the management of gliomas]. (2007) (10)
- Map Dynamics Study of the Lorenz Equations (1997) (10)
- Pulmonary Sarcoid–like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma (2014) (10)
- Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. (2018) (10)
- A Single Mutation in Enzyme I of the Sugar Phosphotransferase System Confers Penicillin Tolerance to Streptococcus gordonii (2009) (9)
- Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases (2016) (9)
- Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. (2018) (9)
- Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification. (2019) (9)
- T-Cell Receptors Binding Orientation over Peptide/MHC Class I Is Driven by Long-Range Interactions (2012) (9)
- Conformational analysis of a stereochemically complete set of cis-enediol peptide analogues. (2002) (8)
- The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites. (2017) (8)
- Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo. (1999) (8)
- Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors (2022) (8)
- COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) (2022) (7)
- Correction: Frequent MAGE Mutations in Human Melanoma (2010) (7)
- A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265). (2016) (7)
- Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. (2021) (7)
- Impact of Orthologous Melan-A Peptide Immunizations on the Anti-Self Melan-A/HLA-A2 T Cell Cross-Reactivity1 (2006) (7)
- Cystathionine‐gamma‐lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy (2021) (6)
- Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience (2020) (6)
- Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. (2021) (6)
- Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma (2018) (6)
- Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. (2021) (6)
- The fourth extracellular loop of the alpha subunit of Na,K-ATPase. Functional evidence for close proximity with the second extracellular loop. (2008) (6)
- Tinkering with nature: the tale of optimizing peptide based cancer vaccines. (2005) (5)
- A Process Mining Approach to Statistical Analysis: Application to a Real-World Advanced Melanoma Dataset (2020) (5)
- Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma (2022) (5)
- Local Alignment Refinement Using Structural Assessment (2008) (5)
- Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology (2021) (5)
- Compact imaging system with single-photon sensitivity and picosecond time resolution for fluorescence-guided surgery with lifetime imaging capability (2013) (4)
- Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. (2021) (4)
- Acute cardiac manifestations under immune checkpoint inhibitors—beware of the obvious: a case report (2021) (4)
- 24LBA Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07) (2009) (4)
- Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma (2022) (4)
- Fourier transform convolution integrals applied to generalized Born molecular volume (2009) (4)
- Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab (2021) (4)
- The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019 (2020) (4)
- Successes and limitations of targeted cancer therapy in melanoma. (2014) (4)
- Construction of Poincaré maps for multiply periodic and chaotic flows (1994) (4)
- Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1). (2021) (4)
- FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients (2014) (4)
- Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
- Human genome meeting 2016 (2016) (3)
- Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology (2020) (3)
- Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital (2022) (3)
- Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes (2020) (3)
- Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. (2021) (3)
- Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma (2022) (3)
- Prediction of Cross-Recognition of Peptide-HLA A2 by Melan-A-Specific Cytotoxic T Lymphocytes Using Three-Dimensional Quantitative Structure-Activity Relationships (2013) (3)
- Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma (2022) (3)
- Structural Prediction of Peptide-MHC Binding Modes. (2022) (3)
- Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events (2022) (3)
- Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry. (2021) (3)
- Effect of Melan-Α/Μart-1-peptide vaccination plus IMP321 on antitumor immunity and clinical benefit in patients receiving autologous PBMCs after lymphodepletion. (2013) (2)
- Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis. (2020) (2)
- Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope (2015) (2)
- Delimiting Maximal CD8 T Cell Function Evidence for a TCR Affinity Threshold (2010) (2)
- Towards a national strategy for digital pathology in Switzerland (2022) (2)
- [Melanoma: a new therapeutic era]. (2011) (2)
- SwissBioisostere 2021: updated structural, bioactivity and physicochemical data delivered by a reshaped web interface (2021) (2)
- Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy (2019) (2)
- Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma (2022) (2)
- [New therapeutic weapons in stage IV melanoma]. (2013) (2)
- [Application of molecular modeling to new therapeutic cancer approaches]. (2007) (2)
- Coexistence of multiple escape mechanisms in a BRAFV600E-mutated cutaneous melanoma treated with vemurafenib. (2013) (2)
- [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]. (2015) (2)
- An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves (2022) (2)
- Inhibitors of the Kynurenine Pathway (2017) (2)
- A process mining approach to real-world advanced melanoma treatments. (2020) (1)
- The Fourth Extracellular Loop of the α Subunit of Na,K-ATPase (2008) (1)
- Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. (2021) (1)
- Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). (2010) (1)
- Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors (2022) (1)
- [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]. (2020) (1)
- Defining and searching for structural motifs using DeepView/Swiss-PdbViewer (2012) (1)
- The cutting edge of metastatic melanoma therapy. (2016) (1)
- Axillary Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma Patients after Previous Axillary Surgery: A Systematic Review (2013) (1)
- [Genomics medicine and oncology]. (2014) (1)
- Molecular Dynamics-based Free Energy Simulations (2008) (1)
- [Together, towards precise oncology!]. (2014) (1)
- Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient (2023) (1)
- Tumor-Antigen Peptide Complexes HLA-A 2 / Melanocyte-Melanoma Antigenically Distinct Crystal Structures of Two Closely Related but C (2001) (1)
- Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA) (2022) (1)
- Digitalization is Fueling a Revolution in Precision Oncology (2021) (1)
- Targeting MAP2K1 mutation with trametinib in a triple wild-type melanoma patient. (2019) (1)
- Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland (2019) (1)
- [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]. (2021) (1)
- Self-Antigen Specific for a Human Tumor-Associated Selection of the Preimmune Repertoire-Chain in the α Prevalent Role of TCR Cerottini (2003) (1)
- SPHN/PHRT - MedCo in Action: Empowering the Swiss Molecular Tumor Board with Privacy-Preserving and Real-Time Patient Discovery (2020) (1)
- 7P Comparison of the clinical utility of two different size next generation sequencing (NGS) gene panels for solid tumours (2020) (1)
- Molecular Modeling of Proteins: From Simulations to Drug Design Applications (2009) (1)
- Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18F-FDG PET/CT and Confirmed by Biopsy. (2022) (0)
- Establishment of CORONET: COVID-19 Risk in Oncology Evaluation Tool to Identify Cancer Patients at Low Versus High Risk of Severe Complications of COVID-19 Infection Upon Presentation to Hospital (2021) (0)
- A differential process mining analysis of COVID-19 management for cancer patients (2022) (0)
- 19P Effects of CTLA-4 single nucleotide polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma (2022) (0)
- LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases (2022) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0358 (2019) (0)
- Silencing of both (cid:2) -TrCP1 and HOS ( (cid:2) -TrCP2) Is Required To Suppress Human Immunodeficiency Virus Type 1 Vpu-Mediated CD4 Down-Modulation (cid:1) (2007) (0)
- Machine learning predicts immunoglobulin light chain toxicity through somatic mutations (2019) (0)
- Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma (2022) (0)
- Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) from the MART-1/Melan-A. (2001) (0)
- Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma (2023) (0)
- Title The peroxisomal enzyme L-PBE is required to preventthe dietary toxicity of medium-chain Fatty acids (2017) (0)
- Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer (2018) (0)
- Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients. (2021) (0)
- AFM imaging reveals the assembly of a P 2 X receptor complex containing P 2 X 2 , P 2 X 4 and P 2 X 6 subunits (2013) (0)
- MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07). (2010) (0)
- Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A (2001) (0)
- 824P Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC) (2022) (0)
- [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. (2016) (0)
- Melan-A / HLA-A 2 T Cell Cross-Reactivity Immunizations on the Anti-Self Impact of Orthologous MelanA Peptide (2006) (0)
- COVID-19 in cancer patients: Update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases (2023) (0)
- [New developments in cancer immunotherapy]. (2008) (0)
- T Cell Response In Vivo + Polymorphism on an Antigen-Specific CD8 Gene b Dramatic Influence of V (1999) (0)
- Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging. (2023) (0)
- A Single Mutation in the Enzyme I of the Sugar (2009) (0)
- Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2022) (0)
- Abstract 10187: Renin-Angiotensin-Aldosterone System Inhibitors and Overall Survival in Cancer Patients Treated with Immune Checkpoint Inhibitors (2021) (0)
- Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts (2019) (0)
- Erratum: T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2K(d)-associated photoreactive peptide derivative (Journal of Biological Chemistry (1999) 274 (3622-3631) (1999) (0)
- The Romand Network of Oncology: bridging the gap of personalised oncology (2019) (0)
- [Impact of COVID pandemic on the detection of skin cancer]. (2021) (0)
- Author Correction: Clinical relevance of tumour-associated macrophages (2022) (0)
- Title: Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients–Report (0)
- Interactive process mining of cancer treatment sequences with melanoma real-world data (2023) (0)
- Structure-based prediction of BRAF mutation classes using machine-learning approaches (2022) (0)
- 1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE) (2021) (0)
- Imaging Life Your Resource for Molecular Imaging Innovation Experts discuss nuclear medicine and molecular imaging ’ s optimistic future at the Molecular Imaging World Summit Scaling the summit of molecular imaging (2019) (0)
- P026. CpG based nano-particle vaccination of melanoma patients induced strong CD8 memory T-cell responses when adjuvanted with imiquimod (2011) (0)
- Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR. (2019) (0)
- Melan-A/HLA-A2 T Cell Cross-Reactivity Immunizations on the Anti-Self Impact of Orthologous Melan-A Peptide (2006) (0)
- Modulation of Human Acid-Sensing Ion Channel 1A Open Channel Inactivation by FRRFamide (2012) (0)
- In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study. (2021) (0)
- Title : Single cell analysis reveals similar functional competence of dominant and nondominant CD 8 T-cell clonotypes (2016) (0)
- The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019 (2020) (0)
- Identification of immune cells in melanoma with single-cell RNA-sequencing (2016) (0)
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
- Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0752 (2021) (0)
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
- Actionable secondary driver mutations in BRAFWT and NRASWT metastatic cutaneous melanoma using the Caris Molecular Intelligence profiling. (2016) (0)
- [Advances in Oncology 2019]. (2020) (0)
- [ENT management of head and neck cutaneous melanoma]. (2020) (0)
- Anticancer Activity of the TAT-RasGAP W Motif Is Required for the X A W (2014) (0)
- Tumor Immunology and Cancer Vaccines T-cell Recognition of Glycolipids : Molecular Requirements for Immunogenicity (2005) (0)
- Abstract B7: MDSC frequencies in peripheral blood of ipilimumab-treated melanoma patients correlate with clinical response and overall survival. (2013) (0)
- Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries (2022) (0)
- Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening (2022) (0)
- Production and characterisation of rationally optimised, anti-melanoma T-cell receptors: a step closer towards immunotherapeutic treatment for patients (2008) (0)
- Foreword Preface to the JMR Special Issue on ‘Dynamic Aspects of Molecular Recognition’ (2010) (0)
- 59P Oncolytic adenovirus-based therapeutics to target or reprogram glioma-associated macrophages (2021) (0)
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial (2014) (0)
- [Oncology: navigating the COVID-19 Pandemic and Steer the Course]. (2020) (0)
- Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0363 (2021) (0)
- T cells: Functional and molecular analysis of vaccine elicited T-cell responses in melanoma (2008) (0)
- 237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries (2022) (0)
- [Oncology: what's new in 2022]. (2023) (0)
- Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma. (2013) (0)
- [Oncology, what's new in 2018]. (2019) (0)
- Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2021) (0)
- Exploratory analysis of multiprotein serum predictors at baseline of progression-free survival of ipilimumab or ipilimumab and nivolumab in the Checkmate-069 study. (2017) (0)
- A Natural Structural Variant of the Mouse TCR β-Chain Displays Intrinsic Receptor Function and Antigen Specificity1 (2006) (0)
- Serum protein predictors of long term survival from combined ipilimumab and nivolumab therapy in metastatic melanoma patients. (2018) (0)
- 3356 Triple wild type melanoma profiling in the Caris Molecular IntelligenceTM registry (2015) (0)
- Baseline serum predictors of clinical response to CTLA4 inhibitor therapy in melanoma patients. (2015) (0)
- Drug design for high school students, high school teachers and the public at large (2015) (0)
- cartoon Speiser, Wieckowski et al PNAS (2015) (0)
- Coming Soon, Volume 37, Issue 3 (2016) (0)
- Development of selective PET tracers for {alpha}5{beta}1 integrin receptors (2012) (0)
- Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. (2015) (0)
- Classification of oncology treatment responses from radiology reports with supervised machine learning (2022) (0)
- Decapeptide Nonapeptide but Not the Corresponding ImmunodominantMART-1 MelanA Melanoma-Specific CD 8 T Cells Recognizes A Novel Population of Human (2007) (0)
- [Locally advanced and metastatic melanoma : novelties]. (2020) (0)
- Mutant CTNNB 1 and histological heterogeneity define metabolic subtypes of hepatoblastoma CRIPPA (2018) (0)
- A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma (2016) (0)
- 1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20 (2021) (0)
- Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH). (2020) (0)
- [Present chemoprevention and future vision]. (2005) (0)
- Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma (2022) (0)
- 1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study (2021) (0)
- Development of selective PET tracers for α5β1 integrin receptors (2012) (0)
- Triple wild type melanoma profiling in the Caris Molecular Intelligenceregistry. (2015) (0)
- Crystal structure of indoleamine 2,3-dioxygenase 1 (IDO1) in complex with ferric heme and MMG-0706 (2021) (0)
- Adverse events and estimated costs with the combination of ipilimumab and nivolumab in metastatic melanoma patients. (2021) (0)
- 1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts) (2021) (0)
- Preferential enrichment of myeloid-derived suppressor cell subsets in patients with metastatic melanoma. (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Olivier Michielin?
Olivier Michielin is affiliated with the following schools:
